Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma

被引:0
|
作者
dos Santos, Margarida Varela [1 ,5 ]
Holth, Arild [1 ]
Lindemann, Kristina [2 ,3 ]
Staff, Anne Cathrine [2 ,4 ]
Davidson, Ben [1 ,2 ]
机构
[1] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway
[2] Univ Oslo, Inst Clin Med, Fac Med, N-0316 Oslo, Norway
[3] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Gynecol Oncol, N-0310 Oslo, Norway
[4] Oslo Univ Hosp, Ulleval Hosp, Dept Obstet & Gynecol, N-0450 Oslo, Norway
[5] Ctr Hospitalar Univ Lisboa Cent EPE, Serv Anat Patol, Rua Jose Antonio Serrano, P-1150199 Lisbon, Portugal
关键词
L1CAM; Immunohistochemistry; High-grade serous carcinoma; Effusion; Chemoresistance; Survival; OVARIAN-CANCER; L1; PROGRESSION; DIAGNOSIS; CELLS; CD171;
D O I
10.1016/j.ygyno.2023.07.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. To analyze the expression and prognostic role of L1CAM in tubo-ovarian high-grade serous carci-noma (HGSC).Methods. L1CAM protein expression by immunohistochemistry was analyzed in 644 HGSC (413 effusions, 231 surgical specimens). Expression was analyzed for association with clinicopathologic parameters and survival.Results. L1CAM protein expression was found in 401/413 (97%) effusions and 209/231 (90%) surgical speci-mens, with significantly higher staining extent in effusions (p < 0.001). L1CAM protein expression in effusions was unrelated to clinicopathologic parameters (p > 0.05). In surgical specimens, higher L1CAM expression was significantly related to primary (intrinsic) chemoresistance (p = 0.017). High (>25%) L1CAM expression in HGSC effusions (p = 0.02), older patient age (p = 0.013), FIGO stage IV disease (p < 0.001) and larger residual disease volume (p = 0.001) were significantly associated with shorter overall survival (OS) in univariate analysis. In Cox multivariate analysis, only FIGO stage (p = 0.001) and residual disease volume (p = 0.003) were indepen-dent prognosticators of OS. L1CAM expression in effusions was unrelated to progression-free survival (PFS). There was no association between L1CAM expression in surgical specimens and survival.Conclusion. L1CAM is overexpressed in HGSC effusions compared to surgical specimens. Its overexpression in effusions is significantly associated with shorter OS, but not independently of established prognostic factors such as FIGO stage and residual disease volume.& COPY; 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:76 / 81
页数:6
相关论文
共 50 条
  • [41] Stemness in high-grade serous carcinoma of tubo-ovarian origin causes multiple immunohistochemical pitfalls: a case report
    Van Bockstal, Mieke R.
    Augusto, David
    JOURNAL OF CLINICAL PATHOLOGY, 2020, 73 (12) : 845 - 846
  • [42] Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance
    dos Santos, Margarida Varela
    Holth, Arild
    Bischof, Katharina
    Davidson, Ben
    CLINICAL & EXPERIMENTAL METASTASIS, 2024, 41 (01) : 69 - 76
  • [43] Adopting a Uniform Approach to Site Assignment in Tubo-Ovarian High-Grade Serous Carcinoma: The Time has Come
    Singh, Naveena
    Gilks, C. Blake
    Hirshowitz, Lynn
    Wilkinson, Nafisa
    McCluggage, W. Glenn
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2016, 35 (03) : 230 - 237
  • [44] Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance
    Margarida Varela dos Santos
    Arild Holth
    Katharina Bischof
    Ben Davidson
    Clinical & Experimental Metastasis, 2024, 41 : 69 - 76
  • [45] Characterization ofTP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma
    Chui, M. Herman
    Boroujeni, Amir Momeni
    Mandelker, Diana
    Ladanyi, Marc
    Soslow, Robert A.
    MODERN PATHOLOGY, 2021, 34 (02) : 490 - 501
  • [46] Stemness in high grade serous carcinoma of tubo-ovarian origin: a challenging immunohistochemical pitfall
    Van Bockstal, M. R.
    Augusto, D.
    VIRCHOWS ARCHIV, 2020, 477 : S304 - S304
  • [47] PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma
    Chen, Hao
    Molberg, Kyle
    Strickland, Amanda L.
    Castrillon, Diego H.
    Carrick, Kelley
    Jiang, Qingping
    Niu, Shuang
    Rivera-Colon, Glorimar
    Gwin, Katja
    Hinson, Stacy
    Lea, Jayanthi
    Miller, David S.
    Zheng, Wenxin
    Lucas, Elena
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2020, 44 (08) : 1050 - 1060
  • [48] Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status
    Marchetti, Claudia
    Ataseven, Beyhan
    Perrone, Anna M.
    Cassani, Chiara
    Fruscio, Robert
    Sassu, Carolina M.
    Apostol, Adriana I.
    Harter, Philipp
    De Iaco, Pierandrea
    Camnasio, Cristina Angela
    Moubarak, Malak
    Giannarelli, Diana
    Scambia, Giovanni
    Fagotti, Anna
    GYNECOLOGIC ONCOLOGY, 2024, 187 : 170 - 177
  • [49] PrOTYPE (Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE): The development and validation of a clinical-grade consensus classifier for the molecular subtypes of high-grade serous tubo-ovarian cancer.
    Talhouk, Aline
    George, Joshy
    Wang, Chen
    Goode, Ellen
    Ramus, Susan
    Doherty, Jennifer
    Bowtell, David
    Anglesio, Michael
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 38 - 38
  • [50] A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis
    Communal, Laudine
    Roy, Noemi
    Cahuzac, Maxime
    Rahimi, Kurosh
    Kobel, Martin
    Provencher, Diane M.
    Mes-Masson, Anne-Marie
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (10)